

PerCP/Cy5.5 anti-mouse IL-10

Catalog # / Size: 3125140 / 100 µg
3125135 / 25 µg

Clone: JES5-16E3

Isotype: Rat IgG2b, κ


Immunogen: *E. coli*-expressed, recombinant mouse IL-10

Reactivity: Mouse

Preparation: The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Concentration: 0.2




Th2-polarized lymphocytes from a C57BL/6 mouse were stimulated with PMA + Ionomycin for 6 hours (in the presence of monensin), surface stained with CD3 APC, fixed, permeabilized, and then stained with IL-10 (clone JES5-16E3) PerCP/Cy5.5 (top) or rat IgG2b

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.



* PerCP/Cy5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Application Notes: **ELISA or ELISPOT Detection^{1,9,11:}** The biotinylated JES5-16E3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified JES5-2A5 antibody (Cat. No. 504902/504904) as the capture antibody.

Neutralization^{14:} The LEAF™ purified JES5-16E3 antibody can neutralize the bioactivity of natural or recombinant IL-10.

Flow Cytometry^{3:} The fluorochrome-

labeled JES5-16E3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-10-producing cells within mixed cell populations.

Additional reported applications (for relevant formats) include:
immunohistochemistry³.

**Application
References:**

1. Simkin G, *et al.* 2000. *J. Immunol.* 164:2457.
2. Kitagaki K, *et al.* 2002. *Clin. Diagn. Lab Immunol.* 9:1260.
3. Khanna A, *et al.* 2000. *J. Immunol.* 164:1346.
4. Sander B, *et al.* 1993. *J. Immunol. Methods* 166:201.
5. Litton M, *et al.* 1994. *J. Immunol. Methods* 175:47.
6. Andersson U, *et al.* 1999. *Detection and quantification of gene expression.* New York:Springer-Verlag.
7. Finkelman F, *et al.* 2003. *Curr. Prot. Immunol.* John Wiley & Sons New York. Unit 6.28.
8. Wang W, *et al.* 2004. *FASEB J.* 18:1043.
9. Brummel R and Lenert P. 2005. *J. Immunol.* 174:2429.
10. Lawson BR, *et al.* 2007. *J. Immunol.* 178:5366.
11. Xu G, *et al.* 2007. *J. Immunol.* 179:5358. [PubMed](#)
12. Brummel R, *et al.* 2005. *J. Immunol.* 174:2429. [PubMed](#)
13. Kang YJ, *et al.* 2007. *Stem Cells* 25:1814. [PubMed](#)
14. Seo N, *et al.* 2001. *Immunology.* 103:449. (Neut)

Description:

IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRF1. IL-10 inhibits IFN- γ , TNF- β , and IL-2 production by Th1 clones; inhibits macrophage-mediated IL-1, IL-6, and TNF- α synthesis; suppresses the delayed type hypersensitivity response; stimulates Th2 cell response (which results in elevated antibody production); and promotes mast cell proliferation in combination with IL-4.

**Antigen
References:**

1. Fitzgerald K, *et al.* Eds. 2001. *The Cytokine FactsBook.* Academic Press San Diego.
2. de Waal-Malefy R, *et al.* 1992. *Curr. Opin. Immunol.* 4:314.
3. Howard M, *et al.* 1992. *Immunol. Today* 13:198.